Evolution of blood glucose levels, BMI, and anti-insulin receptor antibodies in blood. Evolution of fasting blood venous glycemia (measured at each administration of chemotherapy or at each assessment of anti-insulin receptor antibodies) and the ability of patient’s serum to inhibit insulin binding to its receptor. The reduction of [125I]insulin binding in the presence of patient’s serum (used at 1:3 dilution) was measured on CHO cells overexpressing insulin receptor as described (18-20). Ins: insulin. Met: metformin.